Drugmakers denied interlocutory appeal in US over EpiPen, Nuvigil settlements
A March 2024 finding that a purported plaintiff class plausibly allege Teva and Cephalon committed an affirmative act when they failed to identify two patent settlements as related in their reporting...To view the full article, register now.
Already a subscriber? Click here to view full article